CCXI   $51.99  0.08% Market Open

ChemoCentryx Inc
Last Events:

2022-10-20 Signal in Stochastic changed from bullish weakening to bullish recovery. The stochastic indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2022-10-20 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2022-10-19 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2022-10-18 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2022-10-17 Signal in Stochastic changed from bullish recovery to bullish weakening. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2022-10-15 Signal in Stochastic changed from bullish weakening to bullish recovery. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2022-10-15 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2022-10-15 Signal in Stochastic changed from bullish recovery to bullish weakening. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.


Current temperature: 0.15
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 35.14
Target: 52.00
High with 50% probability: 68.87
Analyst Recommendations:
Number of estimates 5
Target Price Mean 52.00
Mean unverified/preliminary 52.00 / 52.00
Target Price Low / High 52.00 / 52.00
Median / STD DEV 52.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Sell Buy
rsi Sell Sell -
macd Sell Buy Buy
stoch Buy Sell -
ma20 ActivelyBuy - -
ma50 ActivelyBuy - -
ma100 - - -
Candlestick PatternOct. 18, 2022 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US16383L1061
ceo Dr. Thomas J. Schall Ph.D.
Website https://www.chemocentryx.com
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.